Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Stargardt disease Stories

2011-05-18 14:21:34

Lab Study Shows an Improved Form of Vitamin A May Help Slowing down the aggregation or "clumping" of vitamin A in the eye may help prevent vision loss caused by macular degeneration, research from Columbia University Medical Center has found. Rather than changing the way the eye processes vitamin A, a team of researchers led by Ilyas Washington, a professor in the department of ophthalmology at Columbia's Harkness Eye Institute, decided to focus on changing the structure of vitamin A itself....

2011-05-05 07:30:00

MARLBOROUGH, Mass., May 5, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that interim chairman and CEO Gary Rabin will be presenting at the World Stem Cells & Regenerative Medicine Congress, May 9-11, in London. Mr. Rabin's presentation, titled "Using ESC-Derived RPE Cells for Dry AMD and Stargardt's Disease," will be given on Monday, May 9. In it, he will provide an update on ACT's...

2011-04-26 07:30:00

MARLBOROUGH, Mass., April 26, 2011 /PRNewswire/ -- Advanced Cell Technology ("ACT"; OTCBB:ACTC), a leader in the regenerative medicine space, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a keynote lecture at the 3rd International Collaborative Symposium on Stem Cell Research, April 29-30, in Seoul, South Korea. Dr. Lanza's presentation, "The First Human Embryonic Stem Cell Trials," will be delivered on Friday, April 29, and will feature ACT's...

2011-04-20 08:30:00

MARLBOROUGH, Mass., April 20, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has filed a clinical trial application (CTA) with the European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate its Phase 1/2 clinical trial using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular...

2011-03-10 07:30:00

MARLBOROUGH, Mass., March 10, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has announced a positive opinion of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt's disease. This...

4f4f197a9b0231ab661663bc7f5117071
2010-11-22 09:05:00

A Massachusetts-based company has been given Food and Drug Administration (FDA) approval to conduct a trial in which embryonic stem cells will be used to treat individuals suffering from an eye condition that can lead to blindness. Advanced Cell Technology (ACT), a biotechnology firm that specializes in regenerative medicine, will use the stem cells to treat individuals suffering from Stargardt's Macular Dystrophy, a degenerative condition that affects the part of the retina where incoming...

2010-02-24 14:36:45

Findings could affect future treatments for macular degeneration, stargardt disease & other forms of retinal disease NEW YORK -- An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to...

2010-02-03 07:10:00

LIVONIA, Mich., Feb. 3 /PRNewswire/ -- To commemorate Low Vision Awareness Month this February, Dr. Sheldon Smith, optometrist at Low Vision of Michigan, P.C., is offering free evaluations to patients diagnosed with retinitis pigmentosa (RP), a leading cause of low vision, in hopes that they might be candidates for a brand-new device designed to enhance or restore sight. Until recently, very little was available to help individuals suffering from RP. However, Dr. Smith, New Jersey...

2009-06-11 15:39:26

Advanced Cell Technology, Inc. (OTC:ACTC.PK) and its collaborators at OHSU reported today the long-term safety and efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) produced under manufacturing conditions suitable for human clinical trials. Two important early potential hESC applications are the use of RPE for the treatment of age-related macular degeneration and Stargardt disease, an untreatable form of eye disease that leads to early-onset blindness. The...